Trial Profile
Phase II Randomized Study of Nivolumab With or Without Pazopanib in Metastatic or Unresectable Soft Tissue Sarcomas After One Prior Line of Systemic Therapy or Ineligible to Receive an Anthracycline-based Treatment
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 28 May 2019
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Pazopanib (Primary)
- Indications Soft tissue sarcoma
- Focus Therapeutic Use
- 17 Aug 2017 Planned primary completion date changed from 1 Jun 2020 to 17 Aug 2017.
- 17 Aug 2017 Planned initiation date changed from 1 Oct 2017 to 1 Aug 2017.
- 17 Aug 2017 Status changed from not yet recruiting to withdrawn prior to enrolment.